– USA, MA – Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Kate Walsh, president, and CEO of the Boston Medical Center (BMC) to its board of directors.
“Kate is an exceptional leader with an impressive track record of leading complex and highly successful healthcare organizations of all sizes, and we are thrilled to welcome her to our board,” said CEO, John Evans. “Beam made tremendous progress across our portfolio in 2020, and 2021 is poised to be an even more significant year with preparations underway for the filing of our first base editing Investigational New Drug application. Kate’s unique insights into delivering care for patients in need will be invaluable as we partner with leading clinical investigators and institutions to advance base editing as a novel class of precision genetic medicines.”
About Kate Walsh
Ms. Walsh has extensive experience in leading esteemed healthcare organizations. Before her appointment at BMC, Ms. Walsh served as executive vice president and chief operating officer of Brigham and Women’s Hospital. She previously served as the chief operating officer for Novartis Institutes for Biomedical Research and at Massachusetts General Hospital (MGH) in positions including senior vice president of medical services at the MGH Cancer Center. Before her tenure at MGH, she held positions in several New York City hospitals, including Montefiore, Columbia Presbyterian Medical Center, Saint Luke’s – Roosevelt Hospital Center, and the New York City Health and Hospitals Corporation.
“Having seen firsthand the challenges and hardships that people living with serious or untreatable diseases experience, I am highly encouraged by Beam’s potential to deliver novel, one-time treatments that transform lives,” said Ms. Walsh. “The company’s scientific platform and precision medicine approach could make an impact for so many. I look forward to helping drive this company forward and to partnering with the esteemed Beam team and board of directors on the meaningful milestones ahead.”
Ms. Walsh holds a B.A. and a master’s degree in public health from Yale University. She is a member of the boards of the Federal Reserve Bank of Boston, the Boston Public Health Commission, the Massachusetts Hospital Association, the AAMC Council of Teaching Hospitals, Pine Street Inn, and Yale University.
About Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable, and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
For more information, visit www.beamtx.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.